These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8797683)

  • 21. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team.
    Benson CA; Williams PL; Cohn DL; Becker S; Hojczyk P; Nevin T; Korvick JA; Heifets L; Child CC; Lederman MM; Reichman RC; Powderly WG; Notario GF; Wynne BA; Hafner R
    J Infect Dis; 2000 Apr; 181(4):1289-97. PubMed ID: 10762562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disseminated Mycobacterium avium complex disease in patients with AIDS.
    Benson C
    AIDS Res Hum Retroviruses; 1994 Aug; 10(8):913-6. PubMed ID: 7811542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Another perspective on MAC prophylaxis. Interview by Gordon Nary.
    Pierce M
    J Int Assoc Physicians AIDS Care; 1995 Aug; 1(7):16-8. PubMed ID: 11362746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rifabutin prophylaxis for Mycobacterium avium complex infection in patients with AIDS.
    Siegal FP
    Clin Infect Dis; 1996 Apr; 22 Suppl 1():S23-30; discussion S30-2. PubMed ID: 8785252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum interleukin-6 (IL-6), IL-10, tumor necrosis factor (TNF) alpha, soluble type II TNF receptor, and transforming growth factor beta levels in human immunodeficiency virus type 1-infected individuals with Mycobacterium avium complex disease.
    Havlir DV; Torriani FJ; Schrier RD; Huang JY; Lederman MM; Chervenak KA; Boom WH
    J Clin Microbiol; 2001 Jan; 39(1):298-303. PubMed ID: 11136787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rifabutin: a review with emphasis on its role in the prevention of disseminated Mycobacterium avium complex infection.
    Maddix DS; Tallian KB; Mead PS
    Ann Pharmacother; 1994 Nov; 28(11):1250-4. PubMed ID: 7849340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interventions for the prevention of mycobacterium avium complex in adults and children with HIV.
    Uthman MM; Uthman OA; Yahaya I
    Cochrane Database Syst Rev; 2013 Apr; (4):CD007191. PubMed ID: 23633339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Azithromycin in the prophylaxis of opportunistic infections in AIDS.
    McCutchan JA
    Int J STD AIDS; 1996; 7 Suppl 1():34-7. PubMed ID: 8652726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Corneal endothelial deposits in children positive for human immunodeficiency virus receiving rifabutin prophylaxis for Mycobacterium avium complex bacteremia.
    Smith JA; Mueller BU; Nussenblatt RB; Whitcup SM
    Am J Ophthalmol; 1999 Feb; 127(2):164-9. PubMed ID: 10030558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress report: prophylaxis and therapy for MAC.
    Currier J
    AIDS Clin Care; 1996 Jun; 8(6):45-8. PubMed ID: 11363599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Managing HIV. Part 5: Treating secondary outcomes. 5.15 HIV and non-tuberculous mycobacterial infection.
    Hoy JF; Marriott D; Gottlieb T
    Med J Aust; 1996 May; 164(9):543-5. PubMed ID: 8649292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group.
    Shafran SD; Singer J; Zarowny DP; Phillips P; Salit I; Walmsley SL; Fong IW; Gill MJ; Rachlis AR; Lalonde RG; Fanning MM; Tsoukas CM
    N Engl J Med; 1996 Aug; 335(6):377-83. PubMed ID: 8676931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MAC prophylaxis revisited.
    Torres G
    GMHC Treat Issues; 1996 Apr; 10(4):6-7, 10. PubMed ID: 11363706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk-benefit assessment of therapies for Mycobacterium avium complex infections.
    Griffith DE
    Drug Saf; 1999 Aug; 21(2):137-52. PubMed ID: 10456381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rifabutin for MAC questioned.
    Posit Aware; 1995; ():6. PubMed ID: 11362571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of survival and eradication of Mycobacterium avium complex bacteremia (MAC) in AIDS patients in the Canadian randomized MAC treatment trial. Canadian HIV Trials Network Protocol 010 Study Group.
    Singer J; Thorne A; Phillips P; Rachlis AR; Miller M; Gill MJ; Smaill FM; Schlech WF; Senay H; Shafran SD
    AIDS; 1999 Apr; 13(5):575-82. PubMed ID: 10203382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does in vitro susceptibility to rifabutin and ethambutol predict the response to treatment of Mycobacterium avium complex bacteremia with rifabutin, ethambutol, and clarithromycin? Canadian HIV Trials Network Protocol 010 Study Group.
    Shafran SD; Talbot JA; Chomyc S; Davison E; Singer J; Phillips P; Salit I; Walmsley SL; Fong IW; Gill MJ; Rachlis AR; Lalonde RG
    Clin Infect Dis; 1998 Dec; 27(6):1401-5. PubMed ID: 9868650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hold the big MAC.
    Young A
    Notes Undergr; 1996 Apr; (no 32):6. PubMed ID: 11363450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uveitis associated with rifabutin therapy: a clinical alert.
    Petrowski JT
    J Am Optom Assoc; 1996 Nov; 67(11):693-6. PubMed ID: 8979664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS.
    Moore RD; Chaisson RE
    AIDS; 1995 Dec; 9(12):1337-42. PubMed ID: 8605053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.